1. The landscape of new drugs in extranodal NK/T-cell lymphoma
   Liang Wang et al, 2020, Cancer Treatment Reviews CrossRef
2. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma
   John de Groot et al, 2022, CNS Oncology CrossRef
3. Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
   Ka-Hei (Murphy) Sun et al, 2022, Diagnostics CrossRef
4. Oxymatrine ameliorates rheumatoid arthritis by regulation of Tfr/Tfh cell balance viatheTLR9‐MyD88‐STAT3 signaling pathway
   Gan Cao et al, 2023, Journal of the Science of Food and Agriculture CrossRef
5. Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity
   Xiao-Guang Yang et al, 2019, Frontiers in Oncology CrossRef
6. Strategies for Targeting the JAK ‐ STAT Pathway in Lymphoid Malignancies
   David J. Feith et al, 2023, Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies CrossRef
7. Glycoprotein PTGDS promotes tumorigenesis of diffuse large B-cell lymphoma by MYH9-mediated regulation of Wnt–β-catenin–STAT3 signaling
   Shunfeng Hu et al, 2022, Cell Death & Differentiation CrossRef
8. Combination of Gemcitabine and Thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer/T-cell lymphoma
   Meiyu Chen et al, 2021, International Immunopharmacology CrossRef
9. Novel target and treatment agents for natural killer/T-cell lymphoma
   Xiao-Peng Tian et al, 2023, Journal of Hematology & Oncology CrossRef
10. STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner
    Shanshan Sun et al, 2018, Clinical Cancer Research CrossRef
11. Extranodal NK-/T-cell lymphoma, nasal type: what advances have been made in the last decade?
    Renata de Oliveira Costa et al, 2023, Frontiers in Oncology CrossRef